Kiniksa Pharmaceuticals International KNSA · USD
Health Care · US listing · 🇺🇸 United States
98.76
+5.22%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Kiniksa Pharmaceuticals International
From its filings with the US Securities and Exchange Commission
Kiniksa Pharmaceuticals International is based in London. Its shares trade on Nasdaq under the ticker KNSA. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $677.6m and net income of $59.0m. At that date it held total assets of $763.6m and shareholders' equity of $567.6m.
We are a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Our portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation.
ARCALYST is an interleukin-1α (“IL-1α”) and interleukin-1β (“IL-1β”) cytokine trap. In 2017, we licensed ARCALYST from Regeneron, which discovered and initially developed the drug. Our exclusive license to ARCALYST from Regeneron includes worldwide rights, excluding the Middle East and North Africa, for all applications other than those in oncology and local administration to the eye or ear.
We received FDA approval of ARCALYST for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children 12 years and older in March 2021. Recurrent pericarditis is a painful inflammatory cardiovascular disease with an estimated United States prevalent population of approximately 40,000 patients seeking and receiving medical treatment. ARCALYST is also approved in the United States for the treatment of Cryopyrin-Associated Periodic Syndromes (“CAPS”), including Familial Cold Autoinflammatory Syndrome (“FCAS”) and Muckle-Wells Syndrome in adults and children 12 years and older, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist (“DIRA”) in adults and children weighing 10 kg or more.
Quoted from its 10-K, filed 24 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 24 May 2018
- Employees
- 366
- Website
- kiniksa.com ↗
- Head office
- 105 PICCADILLY, SECOND FLOOR, LONDON, W1J 7NJ
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Sanjiv PatelChairman of the Board, Chief Executive Officer, since 2015$6.1m
- Mr. Mark RagosaChief Financial Officer, Senior Vice President
- Mr. Eben TessariChief Operating Officer, Senior Vice President$1.9m
- Mr. Ross MoatSenior Vice President and Chief Commercial Officer
- Mr. John PaoliniSenior Vice President and Chief Medical Officer$1.9m
- Mr. Michael MegnaChief Accounting Officer, Group Vice President - Finance
- Dr. Felix BakerLead Independent Director$331,702
- Dr. Stephen BiggarIndependent Director$292,602
- Mr. G. Bradley ColeIndependent Director$286,002
- Dr. Richard LevyIndependent Director$290,402
- Mr. Thomas MalleyIndependent Director$301,002
- Ms. Tracey McCainIndependent Director$283,527
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 26
- Environment
- 4
- Social
- 36
- Governance
- 38
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Kiniksa Pharmaceuticals International PLC focuses on biopharmaceuticals for debilitating diseases with unmet medical needs.
- Rilonacept and Mavrilimumab are key therapeutic programs targeting interleukin-1 and GM-CSF pathways.
- The company has 366 employees dedicated to developing innovative treatments in Health Care sector.
Weaknesses
- Kiniksa operates from Hamilton, a city not known for biotech innovation hubs.
- The company has no products approved in the United States market yet.
- Kiniksa's business is limited to biotechnology without diversification into other sectors.
Opportunities
- Kiniksa can expand its Rilonacept program into new markets like Europe and Asia.
- Mavrilimumab has potential for approval in rheumatoid arthritis and other autoimmune conditions.
- The Health Care sector growth in emerging markets offers Kiniksa new commercial opportunities.
Threats
- Kiniksa faces competition from established biotech firms in the Health Care sector.
- Regulatory delays could impact the approval timeline for KPL-716 and KPL-404.
- Economic downturns may reduce funding for biopharmaceutical research and development.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.